Liver mass containing normal bile ducts in an Alagille patient: A case report

Stefanie Parisien-La Salle, Med. Int., Justin Côté-Daigneault, M.D., Laurent Garel, M.D., Luc Laurier Oligny, M.D. and Fernando Alvarez, M.D.

INTRODUCTION

Alagille syndrome (AGS) is an autosomal dominant disease with variable expression that results from mutations in JAGGED1 and NOTCH2, which are the genes involved in the pathway associated with normal biliary development. The main feature is a paucity of the interlobular bile ducts, leading to chronic cholestasis in 91% of patients. Other major abnormalities defining this syndrome are congenital heart disease (85%), butterfly vertebrae (87%), embryotoxon (88%) and characteristic facial traits (95%). Clinical diagnosis is possible when the patient presents at least three of these major signs.

http://dx.doi.org/10.5546/aap.2015.eng.e223

CASE REPORT

At four weeks of age, the patient was hospitalized for neonatal cholestasis and pale coloured stools. His initial liver function tests showed hepatic injury and obstructive cholestasis (ALT: 74U/L [N: 5-34] AST: 154U/L [N: 11-43], gamma-GT: 81U/L [N:3-43]), and an elevated conjugated bilirubin (109umol/L [N:0-4]). AGS was diagnosed one month later due to additional clinical findings including butterfly vertebrae located in T5, characteristic facial traits, peripheral pulmonary stenosis and persistent jaundice. A liver biopsy revealed an unspcific picture of neonatal cholestasis, associated with paucity of interlobular bile ducts. The identification of JAG1 r184c + mutation came four years later to confirm the initial diagnosis of a partial AGS.

At the age of 12, the patient started presenting a liver heterogeneity; the caudate lobe became hypertrophied.

Four years later, the ultrasound showed a heterogeneous lesion measuring 6.5 cm x 4.4 cm, located in the caudate lobe of the liver. The diagnosis of focal nodular hyperplasia (FNH) seemed most likely at the time.

Over the following year, the mass grew in size leading to further investigations. An abdominal MRI was then performed (Figure 1). The imaging showed that the mass had reached 10.7 cm x 12.5 cm x 6.9 cm and was well delimited. After gadolinium administration, the mass had a uniform enhancement and there were no sign of early wash out. The mass did not have a fatty content. There were no enlarged hilar lymph nodes. The spleen had reached 23 cm in transverse diameter, indicating the development of portal hypertension. The clinical, biochemical and radiological findings did not meet the criteria of a hepatocarcinoma. The alpha-fetoprotein remained at a normal level and a biopsy of the right and caudate lobe was performed, revealing that the mass was composed of normal liver, without ductopenia. In the sample, six out of seven portal spaces were normal and the seventh showed a subtle hepatitis with no fibrosis. The hepatocytes had a slight intracytoplasmic cholestasis that was
described as moderate in the normal liver biopsy (Figure 2).

**DISCUSSION**

AGS is thought to be a chronic disease with ductopenia. The mechanism underlying the bile duct paucity is not completely understood in humans. In normal cells, the JAGGED1 ligand activates the NOTCH receptors on bipotential hepatoblasts, leading to differentiation into cholangiocytes and intrahepatic bile ducts genesis. Spontaneous appearance of normal bile ducts is a rare phenomenon.

There seems to be an important vascular involvement in the development of abnormal ducts. Indeed, it has been shown in mice that mutating JAGGED1 in the mesenchyme of the portal vein leads to the AGS hepatic phenotype. This can be explained by the fact that bile ducts originate from the bi-potential cells lining the mesenchyme of the portal vein. In AGS, the mutated gene alters the signalisation to the

---

**Figure 1. MRI showing a hypertrophy of the caudate lobe; a) axial, b) transverse plan**

---

**Figure 2. H&E x 100**

a) Extensive fibrosis, with micro-nodules in the right lobe of the liver. b) Normal liver, in the biopsy from the caudate lobe. Immunohistochemistry detecting cytokeratin 19 expression. c) Absence of interlobular bile ducts in the right lobe. d) Presence of interlobular bile ducts in the normal liver.
hepatoblast leading to abnormal cholangiocyte development. So, for the liver to have normal bile ducts the mutation needs to spare the cells that were destined to vascularise the caudate lobe, for example the patient could have a congenital mosaicism. This scenario is possible seeing the caudate lobe is embryonically and anatomically independent of the right and left liver and the main portal fissure. Another possibility is that there is an alternate pathway to ductal formation. Bile duct regeneration is theoretically possible without NOTCH signalling; however it has only been identified in murine experiments. The enlargement of the caudate lobe may be explained by the venous drainage of the liver. The caudate lobe drains directly into the inferior vena cava, as the rest of the liver drains into the hepatic veins first. A cirrhotic liver causes occlusion of the hepatic veins, leading to greater blood flow through the caudate lobe. Considering the particular vascular anatomy of the caudate lobe during foetal life, we can speculate that the normal JAGGED gene in this patient was only expressed in the caudate lobe allowing a normal development of bile ducts.

In conclusion, Alagille Syndrome remains a severe disease with a 62% overall survival rate at 20 years. We hope this case may shed some light on the pathogenesis behind AGS and help in the better management and treatment of this disease.

REFERENCES